Dehydroepiandrosterone (DHEA) effects on HIV replication and host immunity: a randomized placebo-controlled study

Area of Science:

• Endocrinology
• Immunology
• Infectious Diseases

Background:

• Dehydroepiandrosterone (DHEA) shows potential immunomodulatory effects and benefits for mood and quality of life.
• Preliminary studies suggest DHEA may inhibit HIV-1 expression in latent infections, indicating possible use as an adjunct to antiretroviral therapy.

Purpose of the Study:

• To evaluate the impact of DHEA on latent HIV infection, persistent viral replication, immune function, and non-immune health restoration.
• To assess DHEA's efficacy as an adjunctive therapy in patients with suppressed HIV viremia.

Main Methods:

• A 24-week randomized, double-blind, placebo-controlled trial involving 40 HIV patients on stable antiretroviral therapy.
• Participants received DHEA or placebo for 12 weeks, followed by open-label DHEA for another 12 weeks.
• Monitoring included viral load assays, HIV cultures, immunologic assessments, hormonal levels, body composition, and quality of life questionnaires.

Main Results:

• DHEA supplementation was confirmed by increased plasma levels of DHEA, DHEA(S), and androstenedione.
• A trend towards increased infectious HIV titers was observed in the DHEA group, with no significant change in plasma HIV RNA.
• No significant improvements were noted in immune function, lean muscle mass, or bone density; however, quality of life significantly improved.

Conclusions:

• DHEA supplementation in HIV patients with suppressed viremia enhances quality of life.
• DHEA did not demonstrate beneficial antiviral, immunomodulatory, hormonal, or body composition effects in this population.
• Routine use of DHEA as an adjunctive therapy for HIV is not recommended based on these findings.